Evaluation of All'InCath in Peripheral Vasculature Percutaneous Transluminal Angioplasty.

Vascular Diseases Clinical Trial

Official title:

Clinical Evaluation of the All'InCath Contrast Balloon Catheter 035M When Used for Peripheral Vasculature Percutaneous Transluminal Angioplasty.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05497440
• Other study ID #: CSP-0003
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 2022
• Est. completion date: March 2023

Study information

• Verified date: August 2022
• Source: NexStep Medical
• Contact: Philippe Urbain
• Phone: +33611724585
• Email: purbain[@]nexstepmedical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this post-market clinical study is to obtain additional data on the safety and performance of the All'InCath 035M Balloon Dilatation Catheter when used per its Instructions for Use (IFU) during percutaneous transluminal angioplasty procedures in clinical practice.

Description:

The All'InCath Contrast Balloon Catheter 035M Balloon Dilatation Catheter has received 510(k) clearance for Percutaneous Transluminal Angioplasty in the peripheral vasculature, for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae, and angiographic visualization of the vasculature when combined with the delivery of radiopaque contrast media (K191275).

The objective of this post-market clinical study is to obtain additional data on the safety and performance of the All'InCath 035M Balloon Dilatation Catheter, including device-related perioperative adverse events, vascular patency, visualization of the target area, duration of intervention, level of radiation exposure, dose of contrast agent, post-procedural adverse events and physician's feedback, when used per its Instructions for Use (IFU) during percutaneous transluminal angioplasty procedures in clinical practice.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: March 2023
• Est. primary completion date: March 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A participant will be eligible to participate in the study if all of the following apply:

• Ability to provide Informed Consent

• Can also be executed by the legal designated representative or the witness

• As per the Principal Investigator's practices as per standard of care, the subject is indicated for PTA in the peripheral vasculature, including iliac, femoral, popliteal, and renal arteries, and any treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.

• Male or female >18 years old.

• Life expectancy >1 year

Exclusion criteria

The following subjects will be excluded from the study if any of the following criteria are met:

• Unstable coronary artery disease or any other uncontrolled comorbidity.

• Myocardial infarction or stroke within two (2) months before baseline evaluation.

• Previous peripheral bypass or procedure that includes the target vessel.

• Known, untreated allergy or other contraindications to contrast agents or medications used during or after PTA.

• Non-correctable bleeding diathesis, platelet dysfunction, thrombocytopenia, or any other known coagulopathy.

• The use of antiplatelet or anticoagulant therapy is contraindicated.

• Any planned major surgical or interventional procedure within 30 days after the study procedure.

• Females who are breast-feeding or child-bearing potential and not using a medically reliable method of contraception (as defined below) for the entire study duration:

• medically reliable contraception defined as: oral, injectable, or implantable contraceptives, intrauterine contraceptive devices, or those not using another method deemed by the Investigator to be sufficiently reliable.

• subjects who are surgically sterilized / hysterectomized or post-menopausal for longer than two (2) years are not considered childbearing potential.

• Positive pregnancy test result in women of child bearing potential or is breast-feeding.

• Incapacitated individuals and those with psychiatric disorders that could interfere with the provision of informed consent, completion of tests, therapy, follow-up or general study compliance.

• Participation in another study with investigational drug or device within the 30 days preceding and during the present study.

Related Conditions & MeSH terms

• Vascular Diseases

Intervention

Device:
• All'InCath CBC 035M Balloon Dilatation Catheter
All participants will undergo the same intervention. Peripheral Vasculature Percutaneous Transluminal Angioplasty and Control Angiography.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
NexStep Medical

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Periprocedural Serious adverse events	Freedom from device related periprocedural adverse events and complications during PTA procedure (e.g., loss of guidewire, misdirection of catheter, vessel wall perforation or dissection requiring treatment).	During procedure
Primary	Vascular patency	Vascular patency immediately post-procedure with adequate capability to ensure injection medium contrast into the vessel with a good visualization of the targeted area.	immediately post-procedure
Secondary	Duration of the intervention (PTA)	Performance of the All'InCath Contrast Balloon Catheter 035M	Time of the procedure
Secondary	Level of radiation exposure during PTA (mGy).	Efficiency and Safety of the All'InCath Contrast Balloon Catheter 035M	During procedure
Secondary	Dose of contrast agent injected at the targeted location (mL).	Safety and performance of the All'InCath Contrast Balloon Catheter 035M	During procedure
Secondary	Investigator's feedback	Evaluation of the function of the All'InCath Contrast Balloon Catheter 035M	During procedure
Secondary	Major adverse events during hospitalization until discharge	Safety of the All'InCath Contrast Balloon Catheter 035M	before hospital discharge or 24hours after the index-procedure which ever occurs first